Product image of Jemperli (Dostarlimab) supplied by GNH India

Jemperli

Active Ingredient:
Dostarlimab
Origin:
EU

Jemperli (Dostarlimab)

Dostarlimab, the active ingredient in Jemperli, is a monoclonal antibody presented as a lyophilized powder for solution for infusion for intravenous use. It treats dMMR/MSI‑H advanced or recurrent endometrial cancer in adult patients.

GNH India supplies Jemperli as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Glaxosmithkline (Ireland) Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

Jemperli is a PD‑1 inhibitor used in the management of cancers that exhibit deficient mismatch repair or high microsatellite instability.

  • dMMR/MSI‑H advanced or recurrent endometrial cancer: improves disease control in patients whose tumors show these biomarkers.
  • Endometrial cancer (PD‑1 inhibitor therapy): provides an immunotherapy option for patients with specific molecular profiles.
  • Microsatellite instability‑high solid tumours (investigational): being evaluated in clinical studies for broader oncologic use.

How It Works

  • Dostarlimab binds selectively to the programmed death‑1 (PD‑1) receptor on activated T cells, preventing its interaction with the ligands PD‑L1 and PD‑L2. This blockade releases the inhibitory checkpoint, restoring T‑cell mediated anti‑tumour activity and promoting immune‑driven tumour cell elimination.

Side Effects

Jemperli may cause a range of immune‑related adverse reactions.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: loose stools that may require supportive care.
  • Rash or pruritus: skin irritation or itching.
  • Infusion‑related reactions: transient fever, chills, or flushing during administration.

Serious or Rare Side Effects

  • Immune‑mediated pneumonitis: inflammation of lung tissue that can be life‑threatening.
  • Colitis or hepatitis: severe inflammation of the colon or liver requiring immunosuppression.
  • Endocrinopathies: thyroiditis, adrenal insufficiency, or hypophysitis.
  • Severe infusion reactions: anaphylaxis or cardiovascular compromise.
  • Myocarditis: inflammation of heart muscle with potential cardiac dysfunction.

Precautions & Warnings

When using Jemperli, clinicians should observe several safety measures.

  • Monitor for immune‑mediated adverse events: assess organ function regularly.
  • Manage infusion reactions: have emergency medications and monitoring equipment ready.
  • Avoid live vaccines: immunosuppression may reduce vaccine efficacy.
  • Pregnancy and breastfeeding: safety not established; weigh potential risks and benefits.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Jemperli can interact with other therapies that affect the immune system.

Major Interactions (Avoid)

  • Concurrent use with other PD‑1/PD‑L1 inhibitors: increased risk of severe immune toxicity.
  • Combination with systemic immunosuppressants: may diminish therapeutic efficacy.
  • Live vaccines: heightened risk of infection due to immune modulation.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may mask signs of immune‑related adverse events.
  • Anticoagulants: monitor for bleeding if thrombocytopenia develops.
  • Enzyme‑inducing drugs: no known pharmacokinetic effect but clinical response should be observed.

Frequently Asked Questions

Jemperli (dostarlimab) is indicated for the treatment of adult patients with advanced or recurrent endometrial cancer that is deficient in mismatch repair (dMMR) or exhibits high microsatellite instability (MSI‑H). It provides an immunotherapy option by targeting the PD‑1 pathway to enhance anti‑tumour immune responses.

Dostarlimab is a monoclonal antibody that binds to the PD‑1 receptor on T cells, blocking its interaction with PD‑L1 and PD‑L2. This interruption lifts the inhibitory checkpoint, allowing T cells to recognise and attack cancer cells more effectively, thereby restoring immune‑mediated tumour control.

The dosing regimen for Jemperli is determined by the prescribing oncologist based on the patient’s clinical condition, body weight, and treatment protocol. The prescriber sets the infusion schedule and any dose adjustments required during therapy.

Safety of Jemperli in pregnancy or while breastfeeding has not been established. The drug may pose risks to the fetus or infant, so it should only be used if the potential benefit justifies the potential harm. Consultation with a specialist is essential before exposure.

To order Jemperli, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Jemperli (dostarlimab) belongs to the same class as pembrolizumab and nivolumab, sharing the PD‑1 blockade mechanism. Clinical data suggest comparable efficacy in dMMR/MSI‑H tumours, though differences may exist in dosing intervals, safety profiles, and regulatory approvals across regions.

Jemperli is supplied as a lyophilized powder for infusion and must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken before reconstitution.

Jemperli is administered intravenously. The lyophilized powder is reconstituted with a suitable diluent to create a solution for infusion, which is then delivered over a prescribed period under medical supervision, typically in an oncology infusion centre.

Serious risks include immune‑mediated pneumonitis, colitis, hepatitis, endocrinopathies (such as thyroiditis), severe infusion reactions, and myocarditis. Patients should be monitored closely for symptoms like persistent cough, abdominal pain, jaundice, hormonal changes, or cardiac discomfort, and managed promptly.

Jemperli should not be used in patients with known hypersensitivity to dostarlimab or any of its excipients. It is also contraindicated in individuals receiving other PD‑1/PD‑L1 inhibitors concurrently, and caution is advised for patients with active autoimmune diseases or uncontrolled infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dostarlimab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT